Predictivity of Hemogasanalysis and Lung UltraSound in Determining COVID-19 Severity
Launched by IRCCS SAN RAFFAELE · Dec 28, 2020
Trial Information
Current as of May 27, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • SARS - CoV 2 infection confirmed by positive RT-PCR on nasopharyngeal swab
- Exclusion Criteria:
- • impossibility to perform lung ultrasound due to technical limitations.
About Irccs San Raffaele
IRCCS San Raffaele is a prestigious research hospital and clinical trial sponsor based in Milan, Italy, renowned for its commitment to advancing medical science through innovative research and high-quality patient care. As an Institute for Research and Healthcare, it specializes in a wide range of therapeutic areas, including oncology, neurology, and cardiology, and is dedicated to translating scientific discoveries into effective clinical practices. With a multidisciplinary team of experts and state-of-the-art facilities, IRCCS San Raffaele plays a pivotal role in conducting rigorous clinical trials that contribute to the development of novel treatments and improve patient outcomes globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Milan, Mi, Italy
Patients applied
Trial Officials
Paola AM Maffi, MD, PhD
Principal Investigator
IRCCS San Raffaele Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials